Dunad Bags Big Pharma Partner In Protein Degradation Deal With Novartis
$24m Upfront For UK Biotech
Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.
Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.